CHiQ Champions Inclusion and Innovation as Presenting Partner of the German Wheelchair Tennis Open
BERLIN, GERMANY - Media OutReach Newswire - 28 July 2025 - CHiQ, a leading global brand in consumer electronics and smart home appliances, honourably announced its official sponsorship of the 2025 German Wheelchair Tennis Open. Partnering with the German Tennis Federation (DTB), CHiQ is taking a bold step forward through the power of human-centric technology to elevate inclusion, excellence, and social impact in sports. Beyond sponsorship, CHiQ showcases its dedication to public welfare and ESG principles, inclusivity, equality, and sustainability.
CHiQ Champions Inclusion and Innovation as Presenting Partner of the German Wheelchair Tennis Open
Held at the esteemed SCC Berlin tennis club from July 23 to 27, 2025. The German Wheelchair Tennis Open stands as Germany's premier tournament in the sport. As a pivotal event on the UNIQLO Wheelchair Tennis Tour, it will host over 100 elite athletes, including several top-10 global contenders and national champions, competing across singles and doubles in men's, women's, and quad categories, all vying for the coveted Beate Loddenkemper Trophy.
CHiQ's involvement, anchored by the slogan 'Every Serve Counts. Every Life Shines,' extends beyond brand visibility in Germany and across Europe, highlighting its steadfast commitment to ESG leadership by blending intelligent technology with authentic community empowerment, demonstrating how innovation can inspire impact across inclusivity, sustainability, and social wellbeing.
'The partnership with CHiQ marks a significant leap for wheelchair tennis in Germany,' remarked Mr. Simon Papendorf, Managing Director of the DTB. 'Together, we are amplifying the voice of extraordinary disabled athletes, advocating inclusion, and promoting access to barrier-free sport.'
Mr. Feng, General Manager of CHiQ Europe, added, 'The essence of sport transcends competition—it builds connection. At CHiQ, technology goes beyond product to deliver understanding, compassion, and respect. Through this tournament, we showcase the unyielding strength behind every athlete's journey and unlock CHiQ's ongoing philanthropic mission.'
Since entering the European market, CHiQ has embraced a youthful and tech-savvy lifestyle with user-centric innovation at its core. Viewing ESG as a vital extension of brand value, this sponsorship unfolds a new chapter for CHiQ, driven by technology, guided by responsibility, and rooted in everyday impact.
Hashtag: #CHiQ
The issuer is solely responsible for the content of this announcement.
About CHiQ
CHiQ, a brand under the Changhong Group, one of the world's leading global manufacturer of consumer electronics and household appliances, is redefining industry standards with innovative products, intelligent technologies, and a deepening commitment to corporate social responsibility. Its influence continues to grow across global markets, especially in European Market.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
14 minutes ago
- Yahoo
Mainz's Hong Hyun-seok set for Ligue 1 loan
Kicker reports that Mainz midfielder Hong Hyun-seok is set to be loaned out to Nantes. The 14-times-caped Taeguk international only just joined his current Bundesliga outfit from KAA Gent last season. After starting his initial four Bundesliga fixtures under Mainz head coach Bo Henriksen, Hong didn't earn another league start after September of 2024. Hong wrapped up the 2024/25 campaign with 23 league appearances, 19 of them coming in relief. The South Korean's estimated market value plummeted from €9m to €3.5m over the last twelve months. Mainz paid Gent €4m to acquire Hong from the Belgian Pro League side last autumn. He was the German club's most expensive summer signing. Hong never really managed to catch on in the way intended with the Palatinate Club. South Korean teammate Lee Jae-sung continued to thrive while Hong simply couldn't gain traction. Paul Nebel's rise, along with the summer additions of Benedict Hollerbach and Sota Kawasaki, further diminished Hong's prospects of gaining playing time. Kicker reports that Mainz are set to net a €400,000 loan fee as part of the transaction. Hong remains under contract with the Rheinhessen until 2028. Mainz sporting CEO Christian Heidel has directly confirmed Hong's impending loan out to the German magazine. GGFN |
Yahoo
14 minutes ago
- Yahoo
AMG and Montefiore Investment Announce Partnership
AMG to invest in Montefiore, a leading European private equity firm with €5 billion in AUM, focused on the services sector Montefiore has a 20-year track record of consistently delivering top-tier returns by leveraging its differentiated strategy, sector expertise, unique sourcing capability, and value-creation skills Montefiore's management will retain a substantial majority of the firm's equity and continue to lead Montefiore as an independent firm, in line with AMG's partnership approach Partnership further diversifies AMG's business and expands its participation in global private markets WEST PALM BEACH, Fla. and PARIS, July 28, 2025 (GLOBE NEWSWIRE) -- AMG, a strategic partner to leading independent investment management firms globally, today announced that it has entered into a definitive agreement to acquire a minority equity interest in Montefiore Investment ('Montefiore'), a leading middle-market private equity firm in France and southern Europe. Under the terms of the transaction, Montefiore's management will retain a substantial majority of the firm's equity, continue to lead the organization, and maintain full control of its investment process, strategy, and day-to-day operations. AMG's investment will provide Montefiore with capital to further invest in the firm's capabilities and team as well as to enhance its alignment with clients. Founded in 2005, Montefiore is a premier European private equity firm that invests across the services sector in small- and mid-cap companies, scaling them through a systematic and differentiated approach to value creation. Over the course of its twenty-year history, Montefiore has built market-leading capabilities in sourcing investment opportunities through direct, long-term relationships with business owners, and has created value through its operationally intensive and collaborative partnerships with management teams. Led by co-founders Éric Bismuth and Daniel Elalouf and a large team of Partners, the firm manages a flagship series which has raised six generations of funds and two complementary strategies, enabling Montefiore to support companies at different stages of their development and accelerate their transformation. With offices in Paris, Milan, and Madrid, Montefiore manages €5 billion in assets and has achieved strong returns across varied market environments. 'We are pleased to partner with Montefiore, a premier private equity manager with a two-decade track record of delivering exceptional returns to clients,' said Jay C. Horgen, Chief Executive Officer of AMG. 'Montefiore's differentiated value-add approach, which focuses on accelerating profitable and sustainable growth by closely collaborating with management teams, has successfully scaled portfolio companies from local players into sector leaders across Europe while preserving their entrepreneurial spirit and culture. The firm has excellent forward prospects, and AMG's strategic partnership solutions can magnify the firm's long-term success. I am delighted to welcome Éric, Daniel, and their Partners to our Affiliate group.' 'We were drawn to AMG given its 32-year history as a strategic partner to independent firms, long-term orientation, and worldwide reputation as a collaborative partner,' said Mr. Bismuth, Chief Executive Officer of Montefiore. 'Through this partnership, Montefiore will access AMG's broad range of proven strategic capabilities to advance our long-term objectives, while preserving our independence. We are excited to partner with AMG as we continue to build an enduring, multi-generational firm.' As part of the agreement, Mr. Bismuth and Mr. Elalouf have entered into long-term commitments with the firm. The terms of the transaction were not disclosed and the transaction is expected to close in the second half of 2025, subject to customary closing conditions. About AMG AMG (NYSE: AMG) is a strategic partner to leading independent investment management firms globally. AMG's strategy is to generate long-term value by investing in high-quality independent partner-owned firms, through a proven partnership approach, and allocating resources across AMG's unique opportunity set to the areas of highest growth and return. Through its distinctive approach, AMG magnifies its Affiliates' existing advantages and actively supports their independence and ownership culture. As of March 31, 2025, AMG's aggregate assets under management were approximately $712 billion across a diverse range of private markets, liquid alternative, and differentiated long-only investment strategies. For more information, please visit the Company's website at About Montefiore Investment Founded in 2005, Montefiore Investment is a premier private equity firm dedicated to service SMEs and mid-market companies. Montefiore's team of 70 talented employees applies its deep sector expertise to support portfolio companies in their growth and development projects. Montefiore Investment has demonstrated its ability to transform SMEs and midcap companies into true European champions. The firm's performance has established it as a key player in mid-market private equity. With offices in Paris, Milan, and Madrid, Montefiore Investment currently manages €5 billion in equity and invests to finance sustainable and profitable growth for its portfolio companies. Since 2021, Montefiore has also been a shareholder and strategic partner of Starquest, a management company dedicated to investments in innovative companies with a strong environmental impact (GreenTech). Certain matters discussed in this press release issued by Affiliated Managers Group, Inc. ('AMG' or the 'Company') may constitute forward-looking statements within the meaning of the federal securities laws, and could be impacted by a number of factors, including those described under the section entitled 'Risk Factors' in AMG's most recent Annual Report on Form 10-K, as such factors may be updated from time to time in the Company's periodic filings with the SEC, which are accessible on the SEC's website at AMG undertakes no obligation to publicly update or review any forward-looking statements, whether as a result of new information, future developments or otherwise, except as required by applicable law. This release does not constitute an offer of any products, investment vehicles, or services of any AMG Affiliate. From time to time, AMG may use its website as a distribution channel of material Company information. AMG routinely posts financial and other important information regarding the Company in the Investor Relations section of its website at and encourages investors to consult that section regularly. AMG Media & Investor RelationsPatricia Figueroa(617) 747-3300ir@ pr@
Yahoo
14 minutes ago
- Yahoo
Boehringer Ingelheim and Re-Vana Therapeutics Announce Strategic Collaboration to Develop Long-Acting Ophthalmic Therapies
· Up to three development programs per year leading to a potential total deal value exceeding $1 billion contingent on milestone achievements. Ingelheim, Germany, Tampa, Florida, USA, and Belfast, Northern Ireland, UK [28 July 2025] – Boehringer Ingelheim and Re-Vana Therapeutics, a US and UK based developer of ocular therapeutics and ocular drug delivery technologies, today announced a strategic collaboration and license agreement that aims to develop first-in-class extended-release therapies for eye diseases. Globally, millions of people living with eye health conditions face a progressive decline in their independence and connection to the world due to vision loss. With its diverse pipeline in eye health, which includes four assets in Phase II, Boehringer Ingelheim is committed to preserving the retina, protecting people's way of life and preventing vision loss. Treating ophthalmic diseases often requires frequent injections directly into the eye, which can be very burdensome for patients. Re-Vana's drug delivery technology is designed to release treatments slowly over six to 12 months, aiming to drastically reduce how often patients need injections. Lowering the treatment burden could lead to higher treatment compliance, and potentially result in better therapeutic outcomes. Boehringer Ingelheim will explore combining this technology with its unique pipeline in eye health. 'We're looking forward to team up with Re-Vana to push the boundaries of what's possible in eye health,' said Nedim Pipic, Global Head of Mental Health, Eye Health and Emerging Areas at Boehringer Ingelheim. 'Together, we want to tackle the limits of today's treatments – aiming to help people keep their sight, with fewer injections. This partnership is a bold step forward in our mission to protect vision and ease the burden on patients.' 'The strategic collaboration with Boehringer Ingelheim marks a transformational moment for Re-Vana,' said Michael O'Rourke, Re-Vana Chief Executive Officer. 'By combining our extended-release platform with Boehringer Ingelheim's world-class research and development capabilities and eye health pipeline, we strive to bring forward a new generation of long-acting treatments for eye diseases that offer clinical and quality-of-life benefits for patients.' Under the collaboration, Boehringer Ingelheim aims to add up to three projects per year across therapeutic modalities. The companies will jointly oversee Re-Vana's feasibility and development activities for the extended-release programs, with Boehringer Ingelheim assuming sole responsibility for clinical development, regulatory approval, and global commercialization of the products. The terms of the agreement grant Boehringer Ingelheim target exclusivity, and provide for upfront, development, regulatory and commercial milestone payments to Re-Vana, with total potential deal value exceeding $1 billion for the initial three targets, in addition to royalty payments on net sales. Boehringer Ingelheim Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at (Global) or (UK). About Re-Vana Therapeutics Re-Vana Therapeutics Ltd, founded in 2016 as a spin-out from Queen's University Belfast, is an ocular therapeutics and innovative ocular drug delivery company based in Belfast, Northern Ireland, and a wholly owned subsidiary of Re-Vana Holding, Inc., Tampa, Florida. Re-Vana is venture backed with leading US Ophthalmic investors including Visionary Ventures, ExSight Ventures, InFocus Capital Partners and UK investors including QUBIS, TechStart Ventures, Invest Northern Ireland and Clarendon Fund Managers. Re-Vana is currently raising a Series B round for their sustained release anti-VEGF asset. Learn more at Intended Audiences Notice This press release is issued from our Corporate Headquarters in Ingelheim, Germany and is intended to provide information about our global business. Please be aware that information relating to the approval status and labels of approved products may vary from country to country, and a country-specific press release on this topic may have been issued in the countries where we do business. Media Contacts Boehringer Ingelheim: Dr. Reinhard MalinBoehringer Ingelheim Corporate Center GmbH Innovation Unit/Bio Comms, Corp. Affairs Media + PR press@ Linda RuckelBoehringer IngelheimInnovation Unit Re-Vana: Michele Gray Gray Communications, LLCMichele@ 917 449 9250Sign in to access your portfolio
